| scholarly article | Q13442814 |
| P50 | author | Shaun W Jackson | Q49598614 |
| P2093 | author name string | Yan Wu | |
| Simon C Robson | |||
| Keiichi Enjyoji | |||
| Xiaofeng Sun | |||
| Christian Sundberg | |||
| Tomokazu Hoshi | |||
| Eva Cszimadia | |||
| P2860 | cites work | Distinct antitumor properties of a type IV collagen domain derived from basement membrane | Q22253901 |
| RanBPM associates with CD39 and modulates ecto-nucleotidase activity | Q24304417 | ||
| Identification and characterization of CD39/vascular ATP diphosphohydrolase | Q24336540 | ||
| An RGD sequence in the P2Y(2) receptor interacts with alpha(V)beta(3) integrins and is required for G(o)-mediated signal transduction | Q24681126 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM | Q28216348 | ||
| Antitumor activity of IFN-lambda in murine tumor models | Q28585272 | ||
| Focal adhesion kinase: the first ten years | Q28609173 | ||
| Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
| Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression | Q29615344 | ||
| Mechanisms of angiogenesis and arteriogenesis | Q29617257 | ||
| Seven-transmembrane receptors | Q29619896 | ||
| RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1. | Q33292490 | ||
| Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. | Q33835366 | ||
| Signaling angiogenesis via p42/p44 MAP kinase and hypoxia | Q34047250 | ||
| Nomenclature and classification of purinoceptors. | Q34324355 | ||
| Regulation of G protein-coupled receptor signaling by scaffold proteins | Q34973942 | ||
| A2A adenosine receptor protects tumors from antitumor T cells. | Q35016529 | ||
| Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. | Q35098311 | ||
| Integrins in angiogenesis: multitalented molecules in a balancing act. | Q35299292 | ||
| Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. | Q40616267 | ||
| Disordered cellular migration and angiogenesis in cd39-null mice | Q43826717 | ||
| Integrin indecision | Q43851610 | ||
| Chemotactic, mitogenic, and angiogenic actions of UTP on vascular endothelial cells. | Q46436855 | ||
| A mechanism for divalent cation regulation of beta 3-integrins. | Q46457093 | ||
| Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation | Q50336029 | ||
| Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells | Q52163110 | ||
| Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins | Q61631829 | ||
| Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin | Q73844711 | ||
| Modulation of endothelial cell migration by extracellular nucleotides: involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways | Q81668348 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis | Q539568 |
| P304 | page(s) | 1395-1404 | |
| P577 | publication date | 2007-09-06 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice | |
| P478 | volume | 171 |
| Q45848130 | Altered purinergic signaling in CD73-deficient mice inhibits tumor progression |
| Q36086478 | Blockade of extracellular NM23 or its endothelial target slows breast cancer growth and metastasis. |
| Q36906658 | CD39 and CD73 in immunity and inflammation |
| Q33917557 | CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation |
| Q34091467 | CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice |
| Q35798953 | CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression |
| Q35015717 | CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice |
| Q94464383 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers |
| Q37613051 | Chronic hypoxia impairs extracellular nucleotide metabolism and barrier function in pulmonary artery vasa vasorum endothelial cells |
| Q36420128 | Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice |
| Q38023121 | ENTPD1/CD39 is a promising therapeutic target in oncology |
| Q37876541 | Ectonucleotidases as Regulators of Purinergic Signaling in Thrombosis, Inflammation, and Immunity |
| Q36350059 | Ectonucleotidases in Solid Organ and Allogeneic Hematopoietic Cell Transplantation |
| Q27002950 | Ectonucleotidases in Tumor Cells and Tumor-Associated Immune Cells: An Overview |
| Q61764006 | Extracellular ATP and P2 purinergic signalling in the tumour microenvironment |
| Q37198990 | Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors. |
| Q35546643 | Extracellular NM23 Signaling in Breast Cancer: Incommodus Verum |
| Q38870205 | Extracellular purines, purinergic receptors and tumor growth. |
| Q37279466 | Heightened NTPDase-1/CD39 expression and angiogenesis in radiation proctitis |
| Q34038901 | Immunity, inflammation and cancer: a leading role for adenosine |
| Q35136797 | Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer |
| Q30504090 | Improved vascular organization enhances functional integration of engineered skeletal muscle grafts. |
| Q37390515 | Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer |
| Q46026307 | Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. |
| Q34123241 | NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression |
| Q92637629 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy |
| Q89881655 | On the mechanism of anti-CD39 immune checkpoint therapy |
| Q34542781 | Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection |
| Q34658181 | P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell Death |
| Q35121379 | Physiologic and molecular consequences of endothelial Bmpr2 mutation |
| Q38058320 | Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape |
| Q33770947 | Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis |
| Q37222633 | Purinergic regulation of vascular endothelial growth factor signaling in angiogenesis |
| Q30435545 | Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration |
| Q47233864 | Significant Down-Regulation of "Biological Adhesion" Genes in Porcine Oocytes after IVM. |
| Q27650543 | Structural insight into signal conversion and inactivation by NTPDase2 in purinergic signaling |
| Q37681488 | Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patients |
| Q93062525 | Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function |
| Q98164583 | Targeting CD39 in cancer |
| Q38209586 | Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer |
| Q55330380 | Targeting adenosine for cancer immunotherapy. |
| Q46140918 | Targeting immunosuppressive adenosine in cancer |
| Q64071654 | Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy |
| Q36290218 | The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling |
| Q39161005 | The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets |
| Q49787788 | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
| Q62745785 | The role of NK cells and CD39 in the immunological control of tumor metastases |
| Q97435733 | Using Cytometry for Investigation of Purinergic Signaling in Tumor-Associated Macrophages |
| Q34633667 | Vascular CD39/ENTPD1 Directly Promotes Tumor Cell Growth by Scavenging Extracellular Adenosine Triphosphate |
Search more.